

Thank you for your submission to Annals of Medicine and Surgery

Inbox



Annals of Medicine and Surgery <em@editorialmanager.com> Sun, Jul 24, 2022, 9:46 AM

to me

Dear Dr Rosyidi,

Thank you for sending your manuscript Effect of MLC901 on MIR30C-5P, TGF-B, VEGF Expression, Axon Demyelination & Changes in Neuropathic Pain Animals with Circumferential Spinal Stenosis Method for consideration to Annals of Medicine and Surgery. Please accept this message as confirmation of your submission. When should I expect to receive the Editor's decision?

For Annals of Medicine and Surgery, the average editorial time (in weeks) from submission to first decision is: 5.07 and from submission to final decision is: 10.13.

What happens next?

Here are the steps that you can expect as your manuscript progresses through the editorial process in the Editorial Manager (EM).

1. First, your manuscript will be assigned to an Editor and you will be sent a unique reference number that you can use to track it throughout the process. During this stage, the status in EM will be "With Editor".
2. If your manuscript matches the scope and satisfies the criteria of Annals of Medicine and Surgery, the Editor will identify and contact reviewers who are acknowledged experts in the field. Since peer-review is a voluntary service, it can take some time but please be assured that the Editor will regularly remind reviewers if they do not reply in a timely manner. During this stage, the status will appear as "Under Review".

Once the Editor has received the minimum number of expert reviews, the status will change to "Required Reviews Complete".

3. It is also possible that the Editor may decide that your manuscript does not meet the journal criteria or scope and that it should not be considered further. In this case, the Editor will immediately notify you that the manuscript has been rejected and may recommend a more suitable journal.

For a more detailed description of the editorial process, please see Paper Lifecycle from Submission to

Publication: http://help.elsevier.com/app/answers/detail/a_id/160/p/8045/

How can I track the progress of my submission?
You can track the status of your submission at any time
at <http://ees.elsevier.com/AMSU>

Once there, simply:

1. Enter your username: Your username is: rha.ns2010@gmail.com

If you need to retrieve password details, please go
to: http://ees.elsevier.com/AMSU/automail_query.asp

2. Click on [Author Login]. This will take you to the Author Main Menu
3. Click on [Submissions Being Processed]

Many thanks again for your interest in Annals of Medicine and Surgery.

Kind regards,

Dr. Riaz Agha
Editor-in-Chief
Annals of Medicine and Surgery

If you require further assistance, you are welcome to contact our Researcher
Support team 24/7 by live chat and email or 24/5 by
phone: <http://support.elsevier.com>

Your submission

Inbox



Annals of Medicine and Surgery <em@editorialmanager.com> Wed, Jul 27,
2022, 12:22 PM

to me

Annals of Medicine and Surgery
Title: Effect of MLC901 on MIR30C-5P, TGF-B, VEGF Expression, Axon
Demyelination & Changes in Neuropathic Pain Animals with Circumferential Spinal
Stenosis Method

Dear Dr Rosyidi,

Thank you for your recent submission to Annals of Medicine and Surgery.

Before we send your manuscript out for review, we kindly request that you make the following changes/corrections.

Author listing

When submitting a paper all authors must be listed in the submission process with their email addresses. There are discrepancies between the authors listed in the system and the authors presented on the title page: these should be identical, please edit accordingly.

Double anonymized review

Blinded manuscript (no author details): The main body of the paper (including the references, figures, tables and any acknowledgements) should not include any identifying information, such as the authors' names or affiliations. Author contribution and guarantor sections should be removed from the main file and can be placed in the title page.

Table

Please label the table provided in the manuscript file.

To make these amendments, please do the following:

1. Go to this URL: <https://www.editorialmanager.com/amsu/>

2. Enter your login details

3. Click [Author Login]

This takes you to the Author Main Menu.

4. Click [Submissions Needing Approval by Author]

5. Click [Edit Submission]

Please make the necessary changes, rebuild the PDF of your submission, and resubmit it.

We look forward to receiving your completed submission.

Kind regards

Suguna Selvakumar
Editorial Office
Annals of Medicine and Surgery

Please note that the editorial process varies considerably from journal to journal. For more information about the submission-to-publication lifecycle, click here: http://help.elsevier.com/app/answers/detail/p/7923/a_id/160

For further assistance, please visit our customer support site

at <http://help.elsevier.com/app/answers/list/p/7923>. Here you can search for solutions on a range of topics, find answers to frequently asked questions and learn more about EM via interactive tutorials. You will also find our 24/7 support contact details should you need any further assistance from one of our customer support representatives.

In compliance with data protection regulations, you may request that we remove your personal registration details at any time. (Use the following URL: <https://www.editorialmanager.com/amsu/login.asp?a=r>). Please contact the publication office if you have any questions.

Your submission

Inbox



Annals of Medicine and Surgery <em@editorialmanager.com> Mon, Aug 1, 2022, 12:50 PM

to me

Annals of Medicine and Surgery
Title: Effect of MLC901 on MIR30C-5P, TGF-B, VEGF Expression, Axon Demyelination & Changes in Neuropathic Pain Animals with Circumferential Spinal Stenosis Method

Dear Dr Rosyidi,

Thank you for your recent submission to Annals of Medicine and Surgery.

Before we send your manuscript out for review, we kindly request that you make the following changes/corrections.

Author listing

When submitting a paper all authors must be listed in the submission process with their email addresses. There are discrepancies between the authors listed in the system and the authors presented on the title page: these should be identical, please edit accordingly.

Double anonymized review

Blinded manuscript (no author details): The main body of the paper (including the references, figures, tables and any acknowledgements) should not include any identifying information, such as the authors' names or affiliations. Author Contribution and Guarantor sections should be removed from the main file and can be placed in the title page.

Provenance and peer review

Please add the following statement to your manuscript above the references.

Provenance and peer review

Not commissioned, externally peer reviewed.

To make these amendments, please do the following:

1. Go to this URL: <https://www.editorialmanager.com/amsu/>

2. Enter your login details

3. Click [Author Login]

This takes you to the Author Main Menu.

4. Click [Submissions Needing Approval by Author]

5. Click [Edit Submission]

Please make the necessary changes, rebuild the PDF of your submission, and resubmit it.

We look forward to receiving your completed submission.

Kind regards

Suguna Selvakumar

Editorial Office

Annals of Medicine and Surgery

Please note that the editorial process varies considerably from journal to journal. For more information about the submission-to-publication lifecycle, click here: http://help.elsevier.com/app/answers/detail/p/7923/a_id/160

For further assistance, please visit our customer support site at <http://help.elsevier.com/app/answers/list/p/7923>. Here you can search for solutions on a range of topics, find answers to frequently asked questions and learn more about EM via interactive tutorials. You will also find our 24/7 support contact details should you need any further assistance from one of our customer support representatives.

In compliance with data protection regulations, you may request that we remove your personal registration details at any time. (Use the following URL: <https://www.editorialmanager.com/amsu/login.asp?a=r>). Please contact the publication office if you have any questions.

Editor handles AMSU-D-22-01579

Inbox



Annals of Medicine and Surgery <em@editorialmanager.com>

Thu, Aug 4,
2022, 1:07 AM

to me

Ms. Ref. No.: AMSU-D-22-01579

Title: Effect of MLC901 on MIR30C-5P,TGF-B, VEGF Expression, Axon Demyelination & Changes in Neuropathic Pain Animals with Circumferential Spinal Stenosis Method
Annals of Medicine and Surgery

Dear Dr Rosyidi,

Your submission "Effect of MLC901 on MIR30C-5P,TGF-B, VEGF Expression, Axon Demyelination & Changes in Neuropathic Pain Animals with Circumferential Spinal Stenosis Method" will be handled by Editor in Chief Riaz Agha.

You may check on the progress of your paper by logging on to the Editorial Manager as an author.

Thank you for submitting your work to this journal.

Kind regards,

Editorial Manager
Annals of Medicine and Surgery


For further assistance, please visit our customer support site at <http://help.elsevier.com/app/answers/list/p/7923>

Here you can search for solutions on a range of topics, find answers to frequently asked questions and learn more about EM via interactive tutorials. You will also find our 24/7 support contact details should you need any further assistance from one of our customer support representatives.

In compliance with data protection regulations, you may request that we remove your personal registration details at any time. (Use the following URL: <https://www.editorialmanager.com/amsu/login.asp?a=r>). Please contact the publication office if you have any questions.

Editor handles AMSU-D-22-01579

Inbox



Annals of Medicine and Surgery <em@editorialmanager.com> Tue, Aug 9, 2022, 12:28 PM

to me

Ms. Ref. No.: AMSU-D-22-01579
Title: Effect of MLC901 on MIR30C-5P,TGF-B, VEGF Expression, Axon Demyelination & Changes in Neuropathic Pain Animals with Circumferential Spinal Stenosis Method
Annals of Medicine and Surgery

Dear Dr Rosyidi,

Your submission "Effect of MLC901 on MIR30C-5P,TGF-B, VEGF Expression, Axon Demyelination & Changes in Neuropathic Pain Animals with Circumferential Spinal Stenosis Method" will be handled by Assistant Managing and Executive Editor Maliha Agha.

You may check on the progress of your paper by logging on to the Editorial Manager as an author.

Thank you for submitting your work to this journal.

Kind regards,

Editorial Manager
Annals of Medicine and Surgery


For further assistance, please visit our customer support site at <http://help.elsevier.com/app/answers/list/p/7923>

Here you can search for solutions on a range of topics, find answers to frequently asked questions and learn more about EM via interactive tutorials. You will also find our 24/7 support contact details should you need any further assistance from one of our customer support representatives.

In compliance with data protection regulations, you may request that we remove your personal registration details at any time. (Use the following URL: <https://www.editorialmanager.com/amsu/login.asp?a=r>). Please contact the publication office if you have any questions.

Track the status of your submission to Annals of Medicine and Surgery

Inbox



Track your Elsevier submission <no-reply@submissions.elsevier.com> Aug 13, 2022, 4:45 AM

to me

Manuscript Number: AMSU-D-22-01579

Manuscript Title: Effect of MLC901 on MIR30C-5P, TGF-B, VEGF Expression, Axon Demyelination & Changes in Neuropathic Pain Animals with Circumferential Spinal Stenosis Method

Journal: Annals of Medicine and Surgery

Dear Rohadi Rosyidi,

Your submitted manuscript is currently under review. The peer review process can take a while, so we are trying out a new service that allows you to track the peer review status of your submission in more detail. You can access the service here: <https://track.authorhub.elsevier.com?uuid=51cec6b5-8077-42ae-9be2-a8479fd89405>

This page will remain active until the peer review process for your submission is completed. You can visit the page whenever you like to check the progress of your submission. The page does not require a login, so you can also share the link with your co-authors.

We hope you find this service useful.

Kind regards,
Journal Office of Annals of Medicine and Surgery
Elsevier B.V.

Please note this is an automated message and will only be sent once.

For more information and support, please

visit https://service.elsevier.com/app/answers/detail/a_id/5971/supporthub/publishing/

Date: Aug 21, 2022
To: "Rohadi Muhammad Rosyidi" rha.ns2010@gmail.com
From: "Annals of Medicine and Surgery" annalsjournal@elsevier.com
Subject: Your Submission

Ms. Ref. No.: AMSU-D-22-01579

Title: Effect of MLC901 on MIR30C-5P, TGF-B, VEGF Expression, Axon Demyelination & Changes in Neuropathic Pain Animals with Circumferential Spinal Stenosis Method
Annals of Medicine and Surgery

Dear Dr Rosyidi,

I am pleased to inform you that your paper "Effect of MLC901 on MIR30C-5P, TGF-B, VEGF Expression, Axon Demyelination & Changes in Neuropathic Pain Animals with Circumferential Spinal Stenosis Method" has been accepted for publication in Annals of Medicine and Surgery.

This journal is fully open access; all articles will be immediately and permanently free for everyone to read and download. To provide Open Access, this journal has a publication fee which needs to be met by the authors or their research funders. In the next few days, you will be receiving information via email to allow you to choose one of the CC license options, providing funding information and a link to our payment system.

Learn about publishing Open Access in this journal at
<http://www.elsevier.com/journals/Annals-of-Medicine-and-Surgery/2049-0801/open-access-journal>.

Your manuscript will be published online in raw form 4 days from this acceptance.

Below are comments from the editor and reviewers.

We appreciate and value your contribution to Annals of Medicine and Surgery. We regularly invite authors of recently published manuscript to participate in the peer review process. If you were not already part of the journal's reviewer pool, you have now been added to it. We look forward to your continued participation in our journal, and we hope you will consider us again for future submissions.

Yours sincerely,

Dr Riaz Agha
Editorial Office
Annals of Medicine and Surgery

Comments from the editors and reviewers:

Reviewer #1: It is a good trial to see the degree of axon demyelination with some parameter expressions. In this paper, the method of spinal stenosis that makes the animals have neuropathic pain have a different way. ofcourse there is a different between nerve injury due to chemical agents compare with cutting or ligation of the nerve. The degree of axon demyelination should be different. For this kind of research with many parameters, could make many options that we can choose to deal with this kind of illness.

For further assistance, please visit our customer support site at <http://help.elsevier.com/app/answers/list/p/7923>. Here you can search for solutions on a range of topics, find answers to frequently asked questions and learn more about EM via interactive tutorials. You will also find our 24/7 support contact details should you need any further assistance from one of our customer support representatives.

In compliance with data protection regulations, you may request that we remove your personal registration details at any time. (Use the following URL: <https://www.editorialmanager.com/amsu/login.asp?a=r>). Please contact the publication office if you have any questions.

Your Submission

Inbox



Annals of Medicine and Surgery <em@editorialmanager.com> Aug 21, 2022, 3:38 PM

to me

Ms. Ref. No.: AMSU-D-22-01579

Title: Effect of MLC901 on MIR30C-5P,TGF-B, VEGF Expression, Axon Demyelination & Changes in Neuropathic Pain Animals with Circumferential Spinal Stenosis Method
Annals of Medicine and Surgery

Dear Dr Rosyidi,

I am pleased to inform you that your paper "Effect of MLC901 on MIR30C-5P,TGF-B, VEGF Expression, Axon Demyelination & Changes in Neuropathic Pain Animals with Circumferential Spinal Stenosis Method" has been accepted for publication in Annals of Medicine and Surgery.

This journal is fully open access; all articles will be immediately and permanently free for everyone to read and download. To provide Open Access, this journal has a publication fee which needs to be met by the authors or their research funders. In the next few days, you will be receiving information via email to allow you to choose one of the CC license options, providing funding information and a link to our payment system.

Learn about publishing Open Access in this journal at <http://www.elsevier.com/journals/Annals-of-Medicine-and-Surgery/2049-0801/open-access-journal>.

Your manuscript will be published online in raw form 4 days from this acceptance.

Below are comments from the editor and reviewers.

We appreciate and value your contribution to Annals of Medicine and Surgery. We regularly invite authors of recently published manuscript to participate in the peer review process. If you were not already part of the journal's reviewer pool, you have now been added to it. We look forward to your continued participation in our journal, and we hope you will consider us again for future submissions.

Yours sincerely,

Dr Riaz Agha
Editorial Office
Annals of Medicine and Surgery

Comments from the editors and reviewers:

Reviewer #1: It is a good trial to see the degree of axon demyelination with some parameter expressions. In this paper, the method of spinal stenosis that makes the animals have neuropathic pain have a different way. ofcourse there is a different between nerve injury due to chemical agents compare with cutting or ligation of the nerve. The degree of axon demyelination should be different. For this kind of research with many parameters, could make many options that we can choose to deal with this kind of illness.

For further assistance, please visit our customer support site at <http://help.elsevier.com/app/answers/list/p/7923>. Here you can search for solutions on a range of topics, find answers to frequently asked questions and learn more about EM via interactive tutorials. You will also find our 24/7 support contact details should you need any further assistance from one of our customer support representatives.

In compliance with data protection regulations, you may request that we remove your personal registration details at any time. (Use the following URL: <https://www.editorialmanager.com/amsu/login.asp?a=r>). Please contact the publication office if you have any questions.

IMPORTANT – Track your article [AMSU_104489]

Inbox



Elsevier - Article Status <Article_Status@elsevier.com>

Mon, Aug 22,
2022, 2:06 AM

to me

ELSEVIER

Track your article!

Dear Dr Rosyidi,

Your article *Effect of MLC901 on MIR30C-5P, TGF-B, VEGF Expression, Axon Demyelination & Changes in Neuropathic Pain Animals with Circumferential Spinal Stenosis Method* will be published in Annals of Medicine and Surgery.

To track the status of your article throughout the publication process, please use our article tracking service:

<https://authors.elsevier.com/tracking/article/details.do?aid=104489&jid=AMSU&surname=Rosyidi>

For help with article tracking go to [Elsevier Support](#).



We are committed to publishing your article as quickly as possible. We will therefore send you an alert of each next step in the production process where your involvement is required.

Once the expected dispatch date of your proofs is available, you will be automatically alerted by e-mail.

Yours sincerely,
Elsevier Researcher Support

Have questions or need assistance?

Please do not reply to this automated message.

For further assistance, please visit our [Elsevier Support Center](#) where you search for solutions on a range of topics and find answers to frequently asked questions.


You can also talk to our researcher support team by phone 24 hours a day from Monday-Friday and 24/7 by live chat and email.

© 2022 Elsevier Ltd | Privacy Policy <http://www.elsevier.com/privacypolicy>

Elsevier Limited, The Boulevard, Langford Lane, Kidlington, Oxford, OX5 1GB, United Kingdom, Registration No. 1982084. This e-mail has been sent to you from Elsevier Ltd. To ensure delivery to your inbox (not bulk or junk folders), please add Article_Status@elsevier.com to your address book or safe senders list.

IMPORTANT PLEASE TAKE ACTION, Production has begun on your article [AMSU_104489] in Annals of Medicine and Surgery

Inbox



A.Achuthan@elsevier.com

Thu, Aug 25,
2022, 5:52 AM

to me

Our reference: AMSU 104489

Article reference: AMSU_AMSU-D-22-01579

Article title: Effect of MLC901 on MIR30C–5P expression, TGF-B expression, VEGF receptor expression, degree of axon demyelination and changes in neuropathic pain behaviour in experimental animals experiencing neuropathic pain with circumferential spinal stenosis method

To be published in: Annals of Medicine and Surgery

Dear Dr Rosyidi,

Congratulations on your accepted paper! Thank you for choosing to publish in Annals of Medicine and Surgery. Please read this e-mail carefully as it contains important information.

FINALIZE PUBLISHING YOUR ARTICLE:

We work hard to publish our authors' articles online as quickly as possible, so we're happy to report that processing of your manuscript has already begun. To ensure that we publish your article in accordance with your wishes, please now complete these forms

<http://authors.elsevier.com/authorforms/AMSU104489/ab4b1907665df622826907090da20416>

If this link does not work, please copy the entire URL (noting that it may run on to a second line in this message) into your browser. You should log in with your Elsevier Profile credentials, which you may have already created when submitting your article.

CHECK YOUR CONTACT DETAILS:

Please check that your details listed below are correct so we can contact you if needed:

Dr Rohadi Muhammad Rosyidi
Universitas Mataram Fakultas Kedokteran
Neurosurgery Departement
Universitas Mataram Fakultas Kedokteran
Mataram
Indonesia
Phone: not available
Fax: not available
E-mail: rha.ns2010@gmail.com

YOUR REFERENCE NUMBER:

To help us provide you with the best service, please make a note of your article's reference number AMSU 104489 and quote it in all of your messages to us.

If you wish to find out more about the next steps in the publication process and for further help and / or information please visit our Author hub, link below:

https://service.elsevier.com/app/answers/detail/a_id/34514/c/10532/supporthub/publication/

Thank you for your cooperation.

Kind regards,

A Achuthan

Data Administrator
Elsevier
E-Mail: A.Achuthan@elsevier.com

HAVE QUESTIONS OR NEED ASSISTANCE?

For further assistance, Please feel free to talk to our Researcher support team via 24/7 live chat and e-mail or avail our phone support for 24/7. Please visit our Elsevier support Center where you can search for solutions on a range of topics and find answers to frequently asked questions, Get started here:

<http://service.elsevier.com/app/home/supporthub/publishing>

Copyright © 2022 Elsevier B.V. | Privacy
Policy <http://www.elsevier.com/privacypolicy>
Elsevier Limited, The Boulevard, Langford Lane, Kidlington, Oxford, OX5 1GB,
United Kingdom, Registration No. 1982084

Publishing Agreement completed for your article [AMSU_104489]

Inbox



Elsevier - Author Forms <Article_Status@elsevier.com>

Thu, Aug 25,
2022, 8:50 AM

to me

ELSEVIER

Dear Dr Rosyidi,

Thank you for completing the Publishing Agreement Form for your article *Effect of MLC901 on MIR30C–5P expression, TGF-B expression, VEGF receptor expression, degree of axon demyelination and changes in neuropathic pain behaviour in experimental animals experiencing neuropathic pain with circumferential spinal stenosis method*. Please find attached a copy of the "Journal Publishing (License) Agreement" which you completed online on August 25, 2022.

If you have any questions, please do not hesitate to contact us. To help us assist you, please quote our article reference AMSU_104489 in all correspondence.

Now that your article has been accepted, you will want to maximize the impact of your work. Elsevier facilitates and encourages authors to share their article responsibly. To learn about the many ways in which you can share your article whilst respecting copyright, visit: www.elsevier.com/sharing-articles.

We are committed to publishing your article as quickly as possible.

Kind regards,
Elsevier Researcher Support



Have questions or need assistance?

Please do not reply to this automated message.

For further assistance, please visit our [Elsevier Support Center](http://www.elsevier.com/elsevier-support-center) where you search for solutions on a range of topics and find answers to frequently asked questions.

You can also talk to our researcher support team by phone 24 hours a day from Monday-Friday and 24/7 by live chat and email.

© 2022 Elsevier Ltd | Privacy Policy <http://www.elsevier.com/privacypolicy>

Elsevier Limited, The Boulevard, Langford Lane, Kidlington, Oxford, OX5 1GB, United Kingdom, Registration No. 1982084. This e-mail has been sent to you from Elsevier Ltd. To ensure delivery to your inbox (not bulk or junk folders), please add Article_Status@elsevier.com to your address book or safe senders list.

Rights and Access form completed for your article
[AMSU_104489]

Inbox



Elsevier - Author Forms <Article_Status@elsevier.com>

Thu, Aug 25,
2022, 8:50 AM

to me

ELSEVIER

Dear Dr Rosyidi,

Thank you for completing the Rights and Access Form for your article *Effect of MLC901 on MIR30C–5P expression, TGF-B expression, VEGF receptor expression, degree of axon demyelination and changes in neuropathic pain behaviour in experimental animals experiencing neuropathic pain with circumferential spinal stenosis method* on August 25, 2022.

The Order Summary is attached to this email. Your article will be free for everyone to read online as soon as it is published.

If you have any questions, please do not hesitate to contact us. To help us assist you, please quote our article reference AMSU_104489 in all correspondence.

Now that your article has been accepted, you will want to maximize the impact of your work. Elsevier facilitates and encourages authors to share their article responsibly. To learn about the many ways in which you can share your article whilst respecting copyright, visit: www.elsevier.com/sharing-articles.

Kind regards,
Elsevier Researcher Support





Seven strategies for you to create a brand and promote your research

Learn how to give your research the visibility it deserves with these seven strategies.

> [Access module now](#)

Have questions or need assistance?

Please do not reply to this automated message.

For further assistance, please visit our [Elsevier Support Center](#) where you search for solutions on a range of topics and find answers to frequently asked questions.

You can also talk to our researcher support team by phone 24 hours a day from Monday-Friday and 24/7 by live chat and email.

© 2022 Elsevier Ltd | [Privacy Policy](http://www.elsevier.com/privacypolicy) <http://www.elsevier.com/privacypolicy>

Elsevier Limited, The Boulevard, Langford Lane, Kidlington, Oxford, OX5 1GB, United Kingdom, Registration No. 1982084. This e-mail has been sent to you from Elsevier Ltd. To ensure delivery to your inbox (not bulk or junk folders), please add Article_Status@elsevier.com to your address book or safe senders list.

Corrections received - [AMSU_104489]

Inbox



optteam@elsevierproofcentral.com

Thu, Aug 25,
2022, 9:34 AM

to me

This is an automatically generated message. Please do not reply because this mailbox is not monitored.

Dear Dr. Rohadi Muhammad Rosyidi,

Thank you very much for using the Proof Central application for your article "Effect of MLC901 on MIR30C–5P expression, TGF-B expression, VEGF receptor expression, degree of axon demyelination and changes in neuropathic pain behaviour in experimental animals experiencing neuropathic pain with circumferential spinal stenosis method" in the journal "AMSU"

All your corrections have been saved in our system. The PDF summary of your corrections, generated from Proof Central, can be downloaded from the following site for your reference:

https://pcv3-elsevier-live.s3.amazonaws.com/492b9544fad4f520b7b209e2c57ba3/AMSU_104489_edit_report.pdf

To track the status of your article throughout the publication process, please use our article tracking service:

http://authors.elsevier.com/TrackPaper.html?trk_article=AMSU104489&trk_surname
≡

For help with article tracking:
http://support.elsevier.com/app/answers/detail/a_id/90

Kindly note that now we have received your corrections, your article is considered finalised and further amendments are no longer possible.

For further assistance, please visit our customer support site at <http://support.elsevier.com>. Here you can search for solutions on a range of topics. You will also find our 24/7 support contact details should you need any further assistance from one of our customer support representatives.


Yours sincerely,
Elsevier Proof Central team

When you publish in an Elsevier journal your article is widely accessible. All Elsevier journal articles and book chapters are automatically added to Elsevier's SciVerse Science Direct which is used by 16 million researchers. This means that Elsevier helps your research get discovered and ensures that you have the greatest impact with your new article.

www.sciencedirect.com

Dear Author, your article has been accepted

Inbox



Annals of Medicine and Surgery <service@author.email.elsevier.com> Aug 25, 2022, 8:47 PM

to me

If you are unable to view this message correctly, [click here](#)



ELSEVIER

Congratulations on your accepted article!

Dear Author,

We recognize you have a choice of where to submit your research and we thank you for choosing to publish with *Annals of Medicine and Surgery*.

As an expert in the field, you are best placed to explain why your article, **Effect of MLC901 on MIR30C-5P, TGF- β , VEGF Expression, Axon Demyelination & Changes in Neuropathic Pain in Animals with Circumferential Spinal Stenosis Method**, is interesting or impactful to a wider audience. Find out how you can help your article get the visibility it deserves:



[Share and Publish your Research Data](#)



[Researcher Academy](#)



[Get Noticed](#)

We look forward to receiving future manuscripts from you!

Sincerely,

Researcher Engagement Team

[Can we assist you with something? Visit our help page »](#)

Elsevier supports responsible sharing:

Responsible sharing in line with copyright enables publishers to sustain high quality journals and the services they provide to the research community. [Find out how you can share your manuscript in Elsevier journals.](#)

- Find useful tools and resources: [Author Resources.](#)
- For assistance, please visit our [Customer Support](#) site, where you can search for solutions on a range of topics and find answers to frequently asked questions.

Would you like to **update your information**? Amend your profile or publication history by visiting the [Scopus profile and content corrections Support Center.](#)

If you do not wish to receive any further Service messages, please send us an [email](#).



This is a Service message, sent to you by Elsevier STM Journals.

Copyright © 2022 Elsevier Limited All rights reserved. | [Elsevier Privacy Policy](#)
Elsevier Limited, The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB UK

PLEASE TAKE ACTION - Share your article [AMSU_104489]

Inbox



Elsevier - Article Status <Article_Status@elsevier.com>

to me

Wed, Aug 31,
2022, 5:46 AM

ELSEVIER

Share your article!

Dear Dr Rosyidi,

We are pleased to let you know that the final open access version of your article *Effect of MLC901 on MIR30C–5P expression, TGF-B expression, VEGF receptor expression, degree of axon demyelination and changes in neuropathic pain behaviour in experimental animals experiencing neuropathic pain with circumferential spinal stenosis method* is now available online, containing full bibliographic details.

The URL below is a quick and easy way to share your work with colleagues, co-authors and friends. Anyone clicking on the link will be taken directly to the final version of your article on ScienceDirect.



Your article link:

<https://doi.org/10.1016/j.amsu.2022.104489>

Click on the icons below to share with your network:



You can also use this link to download a copy of the article for your own archive. It also provides a quick and easy way to share your work with colleagues, co-authors and friends. And you are welcome to add it to your homepage or social media profiles, such as Facebook, Google+, and Twitter. Other ways in which you can use your final article have been determined by your choice of [user license](#).

To find out how else you can share your article visit www.elsevier.com/sharing-articles.

Kind regards,
Elsevier Researcher Support

Increase your article's impact

Our [Get Noticed](#) guide contains a range of practical tips and advice to help you maximize visibility of your article.

Publishing Lab

Do you have ideas on how we can improve the author experience? Sign up for the [Elsevier Publishing Lab](#) and help us develop our publishing innovations!

Have questions or need assistance?

Please do not reply to this automated message.

For further assistance, please visit our [Elsevier Support Center](#) where you search for solutions on a range of topics and find answers to frequently asked questions.

You can also talk to our researcher support team by phone 24 hours a day from Monday-Friday and 24/7 by live chat and email.

© 2022 Elsevier Ltd | Privacy Policy <http://www.elsevier.com/privacypolicy>

Elsevier Limited, The Boulevard, Langford Lane, Kidlington, Oxford, OX5 1GB, United Kingdom, Registration No. 1982084. This e-mail has been sent to you from Elsevier Ltd. To ensure delivery to your inbox (not bulk or junk folders), please add Article_Status@elsevier.com to your address book or safe senders list.

Dear Author, your article is online, what's next?

Inbox



Annals of Medicine and Surgery <service@author.email.elsevier.com> 2, 2022, 9:06 PM

to me

If you are unable to view this message correctly, [click here](#)



ELSEVIER

Your article is online - time to get noticed!

Dear Author,

Your article **Effect of MLC901 on MIR30C-5P expression, TGF-B**

expression, VEGF receptor expression, degree of axon demyelination and changes in neuropathic pain behaviour in experimental animals experiencing neuropathic pain with circumferential spinal stenosis method is available on ScienceDirect, where over 15 million researchers around the world can read it.

Here are a few tips on getting your article noticed:



[Mendeley](#)



[Researcher Academy](#)



[Sharing and Promoting](#)

Celebrate the publication of your article with a [free digital certificate](#).

Thank you for publishing with us. We look forward to receiving manuscripts from you in the future!

Sincerely,

The Researcher Engagement Team

[Can we assist you with something? Visit our help page »](#)

Elsevier supports responsible sharing:

Responsible sharing in line with copyright enables publishers to sustain high quality journals and the services they provide to the research community. [Find out how you can share your article in Elsevier journals.](#)

- Find useful tools and resources: [Author Resources](#).

- For assistance, please visit our [Customer Support](#) site, where you can search for solutions on a range of topics and find answers to frequently asked questions.

Would you like to **update your information**? Amend your profile or publication history by visiting the [Scopus profile and content corrections Support Center](#).

If you do not wish to receive any further Service messages, please send us an [email](#).



This is a Service message, sent to you by Elsevier STM Journals.

Copyright © 2022 Elsevier Limited All rights reserved. | [Elsevier Privacy Policy](#)
Elsevier Limited, The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB UK